DLL3 and neoplasm: Between September 2016 and February 2019, 1293 patients were pre-screened for DLL3-positive tumor status (Supplementary Table 1); ~287 patients were ultimately screened for the study, and 200 patients were subsequently enrolled and received at least one dose of Rova-T.